Related Experiment Video

Updated: Jul 6, 2026

Assessment of Vascular Function in Patients With Chronic Kidney Disease
08:50

Assessment of Vascular Function in Patients With Chronic Kidney Disease

Published on: June 16, 2014

Use of cardiac biomarkers in end-stage renal disease

Angela Yee-Moon Wang1, Kar-Neng Lai

  • 1University Department of Medicine, Queen Mary Hospital, University of Hong Kong, 102 Pok Fu Lam Road, Hong Kong. aymwang@hku.hk

Journal of the American Society of Nephrology : JASN
|March 7, 2008
PubMed

Insights

Patients with end-stage renal disease (ESRD) face high cardiovascular risks. This review explores B-type natriuretic peptide and cardiac troponin T as biomarkers to help manage this risk.

Area of Science:

  • Nephrology
  • Cardiology
  • Biomarker Discovery

Background:

  • End-stage renal disease (ESRD) is associated with significantly high mortality rates.
  • Cardiovascular disease (CVD) is the primary cause of death in ESRD patients, driven by high rates of cardiac hypertrophy, cardiomyopathy, heart failure, and coronary artery disease.

Purpose of the Study:

  • To review the current evidence on the role and utility of B-type natriuretic peptide and cardiac troponin T.
  • To assess the potential of these biomarkers in profiling and stratifying cardiovascular risk in ESRD patients.

Main Methods:

  • Review of existing scientific literature and clinical evidence.
  • Analysis of the diagnostic and prognostic value of B-type natriuretic peptide and cardiac troponin T.

Main Results:

  • B-type natriuretic peptide and cardiac troponin T show promise as emerging cardiac biomarkers.
  • These biomarkers may complement echocardiography in cardiovascular risk assessment for ESRD patients.

Conclusions:

  • B-type natriuretic peptide and cardiac troponin T can aid in managing cardiovascular risk in ESRD.
  • These biomarkers may improve clinical decision-making and patient outcomes in this high-risk population.

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Drug Dosing in Renal Diseases: Measurement of Glomerular Filtration Rate01:25

Drug Dosing in Renal Diseases: Measurement of Glomerular Filtration Rate

The glomerular filtration rate (GFR) is a critical indicator of kidney health, reflecting how well the kidneys filter blood. Changes in GFR can signal potential kidney impairment, necessitating accurate measurement methods to monitor kidney function effectively.Various molecules can serve as markers for GFR measurement, with the ideal marker meeting several specific criteria. It must freely filter at the glomerulus, avoid reabsorption or secretion by the renal tubules, remain unmetabolized, not...
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration01:28

Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration

Glomerular filtration rate (GFR) can be estimated from serum creatinine using the modification of diet in renal disease (MDRD) formula or the chronic kidney disease–epidemiology collaboration (CKD–EPI) equation. Both methods are widely used in clinical practice to assess kidney function and guide treatment decisions.The MDRD equation does not require weight or height measurements and is normalized to the body surface area of 1.73 m², considered the average adult surface area. This equation is...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...